Klarsen specializes in data marketing for customer winning and engagement. Thanks to its qualified data and proprietary technologies, it allows its customers to increase their marketing performance and net sales. Klarsen disposes of proprietary assets and qualified and reactive databases, in its network of partners and on its own.

Employees

Sector

IT Services & Consulting

More about the company

Quotes

Date	Price	Change	Volume
12/06/26	0.3800 €	-11.83%	29,937
11/06/26	0.4310 €	-6.30%	14,302
10/06/26	0.4600 €	-4.76%	11,531
09/06/26	0.4830 €	-6.76%	3,677
08/06/26	0.5180 €	+2.78%	5,383

Real-time Euronext Paris

More quotes

Income Statement and Estimates

More financial data

Market Closed - Euronext Paris Other stock markets 23:55:00 12/06/2026 HKT			5-day change	1st Jan Change
0.3800 ^EUR	-11.83%		-24.60%	-56.22%

11-03	Klarsen Reports Earnings Results for the Half Year Ended June 30, 2025	CI
30/04/25	Klarsen Reports Earnings Results for the Full Year Ended December 31, 2024	CI

Market Cap	2.88M 3.33M 2.65M 2.48M 4.65M 317M 4.72M 31.3M 12.2M 154M 12.5M 12.23M 533M	P/E Ratio 2023	3.28x	P/E Ratio 2024	-86x
Enterprise Value	3.96M 4.58M 3.65M 3.41M 6.4M 435M 6.5M 43.06M 16.79M 212M 17.19M 16.83M 734M	EV / Sales 2023	1.67x	EV / Sales 2024	0.82x
Free-Float	98.11%	Yield 2023 *	-	Yield 2024	-

11-03	Klarsen Reports Earnings Results for the Half Year Ended June 30, 2025	CI
30/04/25	Klarsen Reports Earnings Results for the Full Year Ended December 31, 2024	CI
16/10/24	Klarsen Reports Earnings Results for the Half Year Ended June 30, 2024	CI
30/04/24	Klarsen Reports Earnings Results for the Full Year Ended December 31, 2023	CI
15/03/24	Acticor Biotech Raises EUR8 Million to Fund Emergency Stroke Treatment Development	MT
07/11/23	Acticor Biotech’s Phase 2/3 Trial for Stroke Drug Combo on Track for 2024 Results	MT
27/10/23	Klarsen Reports Earnings Results for the Half Year Ended June 30, 2023	CI
28/04/23	Klarsen Reports Earnings Results for the Full Year Ended December 31, 2022	CI
09/03/23	Acticor Biotech Secures Funding Until November After EUR12 Million Equity Raise; Stock Sinks 17%	MT
23/12/22	Acticor Biotech Seeks To Meet With US FDA Over Phase 2/3 Study Of Stroke Drug	MT
15/12/22	Twitter to shut down newsletter product Revue next year	RE
06/12/22	Acticor Biotech Wins EU Health Agency Nod For Phase 2/3 Stroke Study Design	MT
06/10/22	Klarsen Reports Earnings Results for the Half Year Ended June 30, 2022	CI

03-04	Klarsen : ALKLA information relative au nombre total de droits de vote et d'actions composant le capital	PU
02-26	Klarsen : ALKLA-Information relative au nombre de droits de vote et actions composant le capital	PU
12-10	Klarsen : ALKLA-Attribution gratuite de BSA	PU
12-09	Klarsen : ALKLA-ACTIVITE 3T2025	PU
11-28	Klarsen : ALKLA-Résultat augmentation de capital	PU

Klarsen Stock

Stocks

ALKLA

FR0011038348

IT Services & Consulting

Valuation: Klarsen

Chart: Klarsen

Latest news : Klarsen

Press Releases: Klarsen

News in other languages: Klarsen

Quotes and Performance

Course Extremes

Managers and Directors: Klarsen

Latest insider transactions

Other IT Services & Consulting

Financials

Company Profile

Quotes

Income Statement and Estimates

06-10	Klarsen : ALKLA – Report des résultats trimestriels et date de publication des comptes annuels – 9 Juin 2026
06-01	Klarsen : Information réglementée – 2026
05-06	Klarsen : Report de la publication des comptes annuels 2025
05-05	Klarsen : ALKLA – Ouverture d’une procédure de redressement judiciaire auprès du Tribunal judiciaire de Strasbourg pour la filiale ITL – Soutien financier de l’actionnaire principal – 05 Mai 2026
05-05	KLARSEN : Ouverture d’une procédure de redressement judiciaire auprès du Tribunal judiciaire de Strasbourg pour la filiale ITL

1 day	-11.83%
1 week	-24.60%
Current month	-29.63%
1 month	-32.62%
3 months	-59.40%
6 months	-60.66%
Current year	-56.22%

1 week	0.38	0.53
1 month	0.38	0.69
Current year	0.22	1.18
1 year	0.22	1.18
3 years	0.22	4.03
5 years	0.22	4.03
10 years	0.11	5.4

Manager	Title	Age	Since
Brice Gazeau CEO	Chief Executive Officer	-	-
Patrice Coffe DFI	Director of Finance/CFO	57	01/07/2008
Jean-Pierre Domingo CTO	Chief Tech/Sci/R&D Officer	-	01/01/2013

Director	Title	Age	Since
Patrice Coffe BRD	Director/Board Member	57	14/06/2010
Gérard Parrou BRD	Director/Board Member	74	27/06/2014
Frédéric Bartoli BRD	Director/Board Member	-	23/03/2011

Date	Insider	Type	Main position	Quantity	% Market Cap.
15/03/22	Parrou Julien	Buy		2,617	0.0790%
28/02/22	Julien Parrou-Duboscq	Buy	Chief Executive Officer	3,011	0.0909%
28/02/22	Julien Parrou-Duboscq	Buy	Chief Executive Officer	11,500	0.3471%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
KLARSEN	-11.83%	-24.60%	-65.45%	-89.73%	1.46M
IBM	-0.95%	-4.42%	-1.80%	+97.85%	256B
ACCENTURE PLC	+1.65%	-4.47%	-45.37%	-45.97%	105B
AUTOMATIC DATA PROCESSING, INC.	+0.96%	-2.47%	-26.27%	+2.59%	90.42B
TATA CONSULTANCY SERVICES LTD.	+1.21%	-1.71%	-37.27%	-33.37%	82.27B
SNOWFLAKE INC.	-3.17%	-2.30%	+11.82%	+34.21%	80.68B
RELX PLC	+1.22%	-4.74%	-36.02%	-3.34%	58.94B
INFOSYS LIMITED	+0.16%	-6.77%	-30.31%	-14.44%	47.53B
FUJITSU LIMITED	-3.18%	-9.22%	-6.00%	+67.91%	35.3B
NEC CORPORATION	-3.02%	-8.79%	-1.75%	+178.66%	32.12B
Average	-1.70%	-6.94%	-23.84%	+19.44%	78.77B
Weighted average by Cap.	-0.34%	-4.25%	-17.17%	+35.21%

	2023	2024
Net sales	5.03M 5.82M 4.63M 4.34M 8.12M 553M 8.25M 54.69M 21.32M 269M 21.84M 21.37M 932M	6.31M 7.31M 5.82M 5.44M 10.2M 695M 10.36M 68.67M 26.77M 338M 27.42M 26.84M 1.17B
Net income	2.75M 3.18M 2.53M 2.37M 4.45M 303M 4.52M 29.93M 11.67M 147M 11.95M 11.7M 510M	-47.76K -55.3K -44.02K -41.2K -77.21K -5.26M -78.41K -520K -203K -2.56M -208K -203K -8.86M
Net Debt	-634K -735K -585K -547K -1.03M -69.82M -1.04M -6.9M -2.69M -33.99M -2.76M -2.7M -118M	1.08M 1.25M 996K 932K 1.75M 119M 1.77M 11.76M 4.58M 57.89M 4.7M 4.6M 200M